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background: Despite the increasing use of dabigatran and rivaroxaban in the older-elderly as an alternative to warfarin to reduce the risk of stroke 
associated with atrial fibrillation, limited information is available on the efficacy and safety of these newer anticoagulants in this population.
methods: We retrospectively reviewed 8,252 patients treated for atrial fibrillation with warfarin, dabigatran or rivaroxaban from Jan. 2011 to 
Jan. 2013 in a community-based health care system. End-points of stroke/transient ischemic attack and bleeding were analyzed in the overall 
population and an older-elderly (≥80 years) subpopulation and then compared to the results published by the authors of the RE-LY and ROCKET AF 
trials, which underrepresented the older-elderly.
results: Of 8,252 total patients, the vast majority was treated with warfarin, but a significant number of patients were managed with dabigatran 
(498 patients) or rivaroxaban (402 patients). The use of dabigatran was significantly higher in the older-elderly subpopulation compared to the 
RE-LY trial (24% vs. 17%), and use of rivaroxaban was significantly higher compared to ROCKET AF (20% vs. unreported). At mean follow-up of 18 
months, there was no significant difference in the rates of stroke or bleeding events (Table).
conclusion: In a community-based, real-world practice, the use of novel anticoagulants in the older-elderly population is substantial and, in this 
nonrandomized analysis, appears to be as effective and safe as warfarin.
